Global Radiopharmaceuticals Market to Reach US$8.9 Billion by the Year 2026

Abstract: Global Radiopharmaceuticals Market to Reach US$8. 9 Billion by the Year 2026 . Radiopharmaceuticals are medicinal solutions containing radioisotopes or radiotracers, which are administered to the patient where they localize to specific organs and emit radiation.

New York, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Radiopharmaceuticals Industry" - https://www.reportlinker.com/p01591554/?utm_source=GNW
Growth in the global market is supported by growing number of nuclear procedures driven by rise in prevalence of cancer, and heart diseases. Significant therapeutic usage of radiopharmaceuticals became possible after the availability of cyclotrons and nuclear reactors which could synthesize large quantities of radioisotopes. The market is further supported by the recent discovery of newer and successful therapeutic applications of radiopharmaceuticals in oncology and cardiology prognosis. Additional impetus from a stream of drug development and testing phases demonstrate the interest surrounding radiopharmaceuticals. Development and progress in this space is anticipated to be fueled by immunology combined with radioisotopes and monoclonal antibodies so as to produce radioisotopes with unprecedented specificity in cancer diagnosis and therapy. Rising popularity of advanced SPECT/CT and PET/CT scanners is also expected to unravel new clinical opportunities.

Amid the COVID-19 crisis, the global market for Radiopharmaceuticals estimated at US$5.3 Billion in the year 2020, is projected to reach a revised size of US$8.9 Billion by 2026, growing at a CAGR of 8.7% over the analysis period. SPECT Radioisotopes, one of the segments analyzed in the report, is projected to grow at a 8.1% CAGR to reach US$4.1 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Pet Radioisotopes segment is readjusted to a revised 9.5% CAGR for the next 7-year period. This segment currently accounts for a 24% share of the global Radiopharmaceuticals market. PET diagnostic radiopharmaceuticals are employed in procedures utilizing PET/CT or PET diagnostic scanners while SPECT diagnostic radiopharmaceuticals are employed in procedures utilizing gamma cameras. Rising popularity of advanced SPECT/CT scanners is expected to unravel new clinical opportunities for SPECT Radioisotopes. Rise in PET procedural volume is expected to provide opportunities for radiopharmaceuticals such as Fluorodeoxyglucose (FDG).

The U.S. Market is Estimated at $2.7 Billion in 2021, While China is Forecast to Reach $545.7 Million by 2026

The Radiopharmaceuticals market in the U.S. is estimated at US$2.7 Billion in the year 2021. The country currently accounts for a 48% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$545.7 Million in the year 2026 trailing a CAGR of 11.3% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.7% and 6.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR while Rest of European market (as defined in the study) will reach US$591.5 Million by the end of the analysis period.

Beta Emitters Segment to Reach $1.6 Billion by 2026

Certain radiopharmaceuticals consist of radionuclides that deliver particulate emission such as beta or alpha radiations or auger electrons possessing the capability to kill diseased tissues. In the global Beta Emitters segment, USA, Canada, Japan, China and Europe will drive the 10.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$744.7 Million in the year 2020 will reach a projected size of US$1.5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$65.1 Million by the year 2026, while Latin America will expand at a 10.5% CAGR through the analysis period.


Select Competitors (Total 137 Featured)

• Actinium Pharmaceuticals, Inc.

• Alliance Medical

• Avid Bioservices Inc

• Bayer HealthCare Pharmaceuticals

• Bracco Diagnostics, Inc.

• Cardinal Health, Inc.

• GE Healthcare

• Ion Beam Applications S.A

• Jubilant Pharma

• Lantheus Medical Imaging Inc.

• Medi-Radiopharma Ltd

• Nordion, Inc.

• Novartis/Advanced Accelerator Applications

• Positron Corporation

• Radiopharm Theranostics Ltd.

Read the full report: https://www.reportlinker.com/p01591554/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of COVID-19 and a Looming Global Recession
2020: A Year of Disruption & Transformation
As the Race between the Virus & Vaccines Intensifies, Where is
the World Economy Headed in 2021?
EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual %
Change) for 2020 through 2022
Pandemic-Led Disruptions Affect Radiopharmaceuticals Supply,
Hindering Nuclear Medicine Procedures in Several Countries
EXHIBIT 2: Imaging Screening Volume % Change 1H 2019 Vs 1H 2020
in US Hospitals
Distribution Bottlenecks amid COVID-19 Crisis Leave Hospitals
Struggling with Supply of Medical Radioisotopes
Nuclear Medicine Services Limp Back to Normalcy after Easing of
COVID-19 Restrictions
COVID-19 Presents Generational Opportunity
An Introduction to Radiopharmaceuticals
Mechanism of Action
Global Market Prospects & Outlook
Key Market Drivers
Market Restraints
Recognition of Intrinsic Cost Benefits: Critical to Market
Acceptance
Classification of Radiopharmaceuticals
Diagnostic Radiopharmaceuticals: The Dominant Segment
Key Drivers
Positron Emission Tomography (PET)
Single Photon Emission Computed Tomography (SPECT)
Therapeutic Radiopharmaceuticals
Global Supply Shortages Continue to Challenge Market Growth
EXHIBIT 3: A Glimpse at Mo-99 Processors Worldwide
EXHIBIT 4: Nuclear Research Reactor Irradiators Worldwide:
A Snapshot
Competitive Landscape
EXHIBIT 5: Radiopharmaceuticals Competitor Market Share
Scenario Worldwide (in %): 2020
World Brands
Recent Industry Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Emergence of Radiotheranostics: Dual-Functioning
Radiopharmaceuticals
Common Radionuclides Used in Theranostic Applications
Radiopharmaceuticals Become Promising for Cancer Theranostics
Changing Role of Radiopharmaceuticals in Diagnostic and
Therapeutic Applications
Advent of New Radiopharmaceuticals Widen Scope
Select New Products
Startups Develop Unique Radiopharmaceutical Solutions
Potential Role of Carbon Dots in Imaging and Theranostics
Nano Radiopharmaceuticals: Promising Role in Therapeutic and
Imaging Applications
Researchers Develop New Nanoparticles to Improve
Radiopharmaceutical Efficiency
Oncoinvent and NPL Develops Unique Method to Measure & Deliver
Dosages in Radiotherapy
Industry Focus Gears up for Innovative Radiopharmaceuticals
with Therapeutic Benefits
Select Commercially Available Therapeutic Radiopharmaceuticals
Role of Radiopharmaceuticals as Diagnostic Technology
PET Eclipses SPECT in Cardiovascular Imaging
EXHIBIT 6: Worldwide Installed Base of Nuclear Imaging
Equipment by Modality, PET Vs SPECT: 2020
Cardiac Amyloidosis Visualization: A Potential Application for PET
Innovative Radiopharmaceuticals to Boost Cardiac Applications
EXHIBIT 7: Fatalities by Heart Conditions - Estimated
Percentage Breakdown for Cardiovascular Disease, Ischemic
Heart Disease, Stroke, and Others
Radiopharmaceuticals: Direct and Targeted Approach for Cancer
Treatment
Rising Cancer Incidence Worldwide Spurs Demand
EXHIBIT 8: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 9: Global Number of New Cancer Cases and Cancer-related
Deaths by Cancer Site for 2020
EXHIBIT 10: Number of New Cancer Cases and Deaths (in Million)
by Region for 2020
Intra-operative Lymphatic Mapping (ILM): Creates New
Opportunities for Radiopharmaceuticals in Cancer Detection
Growing Prominence of Therapeutic Radiopharmaceuticals for
Cancer Care
Rise in Incidence of Neurological Disorders to Drive Growth
Application of PET in Drug Development to Expand Opportunities
Personalized Medicine Drives Nuclear Medicine
EXHIBIT 11: Drug Ineffectiveness for Select Therapeutic
Categories as a Percentage of Patient Population
EXHIBIT 12: Global Personalized Medicine Market: Revenues in
US$ Million for the Years 2019 and 2024
Gallium-68-labeled Radiopharmaceuticals: Production &
Administering Challenges
Radiopharmaceuticals for COVID-19: Role in Diagnosis,
Prognosis, and Therapeutic Uses
Arti?cial Intelligence: A Promising Tool in Radiotherapy and
Radiopharmaceuticals
Aging Global Population: A Vital Demography
EXHIBIT 13: Global Aging Population Statistics for the 65+ Age
Group in Million by Geographic Region for the Years 2019,
2025, 2035 and 2050
EXHIBIT 14: Elderly Population (65+ Years) as a % of Total
Population by Developed, Less Developed and Least Developed
Regions: 2019 & 2030
EXHIBIT 15: Global Cancer Deaths by Age Group (in %) for 2019
Rise in Healthcare Expenditure to Drive Growth
EXHIBIT 16: World Healthcare Expenditure (In US$ Trillion) for
the Years for 2017, 2019, 2021 & 2023
EXHIBIT 17: Elderly Healthcare Expenditure as a % of GDP in the
US, Europe and Japan for 1970, 2010 and 2050
Relevant Aspects of Radiopharmaceutical Production
Regulatory Regime Governing Production and Use of
Radiopharmaceuticals
The Facilitating Innovative Nuclear Diagnostics (FIND) Act, 2021
Challenges Facing Nuclear Medicine Industry

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for
Radiopharmaceuticals by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Radiopharmaceuticals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 3: World 11-Year Perspective for Radiopharmaceuticals by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2016, 2021 & 2027

Table 4: World Current & Future Analysis for SPECT
Radioisotopes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for SPECT Radioisotopes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 6: World 11-Year Perspective for SPECT Radioisotopes by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2021 & 2027

Table 7: World Current & Future Analysis for PET Radioisotopes
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for PET Radioisotopes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 9: World 11-Year Perspective for PET Radioisotopes by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2021 & 2027

Table 10: World Current & Future Analysis for Beta Emitters by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Beta Emitters by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2016 through 2019
and % CAGR

Table 12: World 11-Year Perspective for Beta Emitters by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2021 & 2027

Table 13: World Current & Future Analysis for Alpha Emitters by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Alpha Emitters by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 15: World 11-Year Perspective for Alpha Emitters by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2021 & 2027

Table 16: World Current & Future Analysis for Other Product
Types by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Other Product Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 18: World 11-Year Perspective for Other Product Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2021 & 2027

Table 19: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2016 through 2019
and % CAGR

Table 21: World 11-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2016, 2021 & 2027

Table 22: World Current & Future Analysis for Cardiology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Cardiology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2016 through 2019
and % CAGR

Table 24: World 11-Year Perspective for Cardiology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2021 & 2027

Table 25: World Current & Future Analysis for Neurology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 26: World Historic Review for Neurology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2016 through 2019
and % CAGR

Table 27: World 11-Year Perspective for Neurology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2016, 2021 & 2027

Table 28: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 30: World 11-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2021 & 2027

Table 31: World Current & Future Analysis for Hospitals &
Diagnostic Centers by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Hospitals & Diagnostic
Centers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2016 through 2019 and % CAGR

Table 33: World 11-Year Perspective for Hospitals & Diagnostic
Centers by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2016, 2021 &
2027

Table 34: World Current & Future Analysis for Ambulatory
Surgical Centers by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 35: World Historic Review for Ambulatory Surgical Centers
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 36: World 11-Year Perspective for Ambulatory Surgical
Centers by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2016, 2021 &
2027

Table 37: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 38: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 39: World 11-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Market Overview
Diagnostic Applications Stimulate Future Growth
Demographic Changes Offer Growth Opportunities
EXHIBIT 18: US Elderly Population: Expected Growth Rates (%)
Over the Years 2005-2025
Rising Incidence of Cancer: A Major Growth Driver
EXHIBIT 19: Estimated Number of New Cancer Cases in the US by
Gender and Affected Site for 2021
EXHIBIT 20: Estimated Number of Cancer-Related Deaths in the US
by Gender and Body Site for 2021
EXHIBIT 21: Estimated Number of New Cancer Cases in the US by
State for 2021
EXHIBIT 22: Estimated Number of Cancer-Related Deaths in the US
by State for 2021
Cardiovascular Imaging to Lead Volume Growth
Radiopharmaceuticals Usage Grows in PET Imaging
Radioisotope/Radiopharmaceuticals Supply Scenario
Passing of Medicare Diagnostic Radiopharmaceutical Payment
Equity Act
Market Analytics
Table 40: USA Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 42: USA 11-Year Perspective for Radiopharmaceuticals by
Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2021 & 2027

Table 43: USA Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 44: USA Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 45: USA 11-Year Perspective for Radiopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Cardiology, Neurology and Other Applications for the Years
2016, 2021 & 2027

Table 46: USA Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 47: USA Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 and %
CAGR

Table 48: USA 11-Year Perspective for Radiopharmaceuticals by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2021 & 2027

CANADA
Market Overview
Efforts on to Address Mo-99 Supply Shortage
Market Analytics
Table 49: Canada Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 51: Canada 11-Year Perspective for Radiopharmaceuticals
by Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2021 & 2027

Table 52: Canada Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 53: Canada Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 54: Canada 11-Year Perspective for Radiopharmaceuticals
by Application - Percentage Breakdown of Value Sales for
Oncology, Cardiology, Neurology and Other Applications for the
Years 2016, 2021 & 2027

Table 55: Canada Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 56: Canada Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 and %
CAGR

Table 57: Canada 11-Year Perspective for Radiopharmaceuticals
by End-Use - Percentage Breakdown of Value Sales for Hospitals &
Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2021 & 2027

JAPAN
Market Overview
Market Analytics
Table 58: Japan Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 60: Japan 11-Year Perspective for Radiopharmaceuticals by
Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2021 & 2027

Table 61: Japan Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 62: Japan Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 63: Japan 11-Year Perspective for Radiopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Cardiology, Neurology and Other Applications for the Years
2016, 2021 & 2027

Table 64: Japan Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 65: Japan Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 and %
CAGR

Table 66: Japan 11-Year Perspective for Radiopharmaceuticals by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2021 & 2027

CHINA
Market Overview
Market Analytics
Table 67: China Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 69: China 11-Year Perspective for Radiopharmaceuticals by
Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2021 & 2027

Table 70: China Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 71: China Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 72: China 11-Year Perspective for Radiopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Cardiology, Neurology and Other Applications for the Years
2016, 2021 & 2027

Table 73: China Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 74: China Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 and %
CAGR

Table 75: China 11-Year Perspective for Radiopharmaceuticals by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2021 & 2027

EUROPE
Market Overview
Market Analytics
Table 76: Europe Current & Future Analysis for
Radiopharmaceuticals by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Radiopharmaceuticals by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2016 through 2019 and % CAGR

Table 78: Europe 11-Year Perspective for Radiopharmaceuticals
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2016, 2021 & 2027

Table 79: Europe Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 81: Europe 11-Year Perspective for Radiopharmaceuticals
by Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2021 & 2027

Table 82: Europe Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 83: Europe Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 84: Europe 11-Year Perspective for Radiopharmaceuticals
by Application - Percentage Breakdown of Value Sales for
Oncology, Cardiology, Neurology and Other Applications for the
Years 2016, 2021 & 2027

Table 85: Europe Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p01591554/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001